The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of cilostazol-based triple antiplatelet therapy on ischemi complication after drug-eluting stent implantation) trial

Jung Won Suh, Seung Pyo Lee, Kyungwoo Park, Hyun Jae Kang, Bon Kwon Koo, Young Seok Cho, Tae Jin Youn, In Ho Chae, Dong Ju Choi, Seung-Woon Rha, Jang Ho Bae, Taek Geun Kwon, Jang Whan Bae, Myeong Chan Cho, Hyo Soo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)


It is not clear if anti-restonotic effect of cilostazol is consistent for different types of drug-eluting stents (DES). The purpose of this study was to compare the anti-proliferative effect of cilostazol between DAT and TAT with consideration of confounding influences of DES type. Nine hundred and fifteen patients were randomized to either dual antiplatelet therapy (DAT; aspirin and clopidogrel) or triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol) in the previous CILON-T trial. After excluding 70 patients who received both or neither stents, we analyzed 845 patients who received exclusively PES or ZES, and compared in-stent late loss at 6 months between both antiplatelet regimens (DAT versus TAT). Baseline angiographic and clinical characteristics were similar between the DAT (656 lesions in 425 patients) and the TAT group (600 lesions in 420 patients). The 6-month follow-up angiography was completed in 745 patients (88.2%). Quantitative coronary angiography showed that TAT significantly reduced in-stent late loss (DAT 0.62 ± 0.62 mm versus TAT 0.54 ± 0.49 mm, P = 0.015). Stent type, diabetes or lesion length did not interact with difference of late loss. However, reduction of late loss by cilostazol did not lead to a significant reduction in the rate of target lesion revascularization (TLR) (DAT 7.8% versus TAT 6.9%, P = 0.69) due to a nonlinear relationship found between late loss and TLR. The TAT group showed less in-stent late loss as compared to the DAT group. This was consistently observed regardless of DES type, lesion length, or diabetic status. However, reduction of late loss by cilostazol did not lead to a significant reduction in TLR.

Original languageEnglish
Pages (from-to)853-860
Number of pages8
JournalInternational Heart Journal
Issue number6
Publication statusPublished - 2017 Jan 1



  • Cilostazol
  • Paclitaxel-eluting stent
  • Restenosis
  • Zotarolimus-eluting stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this